A Phase 1 interventional study of Tegoprazan (C1) and Tegoprazan (C1) in Pharmacodynamics, Pharmacokinetics and Healthy Male Volunteers, sponsored by HK inno.N Corporation. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-21.
Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, open-label, active-controlled, single/multiple-dose phase 1 clinical trial to evaluate pharmacokinetics/pharmacodynamics and safety/tolerability of tegoprazan after oral administration in healthy male subjects
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tegoprazan QD, oral administration
Drug: Tegoprazan (C1)
Tegoprazan QD, oral administration
Drug: Tegoprazan (C1)
Tegoprazan BID, oral administration
Drug: Treatment C: Tegoprazan (C1)
Tegoprazan QD, oral administration, for 7 days
Drug: Tegoprazan (C2)
Tegoprazan QD, oral administration, for 7 days
Drug: Tegoprazan (C2)
Esomeprazole QD, oral administration, for 7 days
Drug: Esomeprazole (C2)
Tegoprazan QD, oral administration
Drug: Tegoprazan (C3)
Tegoprazan QD, oral administration. Treatment A
Tegoprazan QD, oral administration. Treatment B
Tegoprazan BID, oral administration
Tegoprazan QD, oral administration, for 7 days. Group 1
Tegoprazan QD, oral administration, for 7 days. Group 2
Esomeprazole QD, oral administration, for 7 days. Group 3
Tegoprazan QD, oral administration
AUC(0-24h) of tegoprazan
Area Under the Curve(0-24h) of tegoprazan
Time frame: up to 7 days
Cmax of tegoprazan
Maximum Plasma Concentration of tegoprazan
Time frame: up to 7 days
Gastric pH
Gastric pH
Time frame: up to 7 days
Serum gastrin concentration
Serum gastrin concentration
Time frame: up to 7 days
Start is estimated for May 2018; primary completion for Aug 2018, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan